Abstract: Antisense oligonucleotides for treating and/or preventing at least one of asthma, allergy, hypereosinophilia, general inflammation and cancer are provided. The oligonucleotides are directed against nucleic acid sequences coding for a receptor selected from the group consisting of a CCR3 receptor and a common sub-unit of IL-3, IL-5 and GM-CSF receptors.
Abstract: Antisense oligonucleotides for treating and/or preventing at least one of asthma, allergy, hypereosinophilia, general inflammation and cancer are provided. The oligonucleotides are directed against nucleic acid sequences coding for a receptor selected from the group consisting of a CCR3 receptor and a common sub-unit of IL-3, IL-5 and GM-CSF receptors.
Abstract: Antisense oligonucleotides for treating and/or preventing at least one of asthma, allergy, hypereosinophilia, general inflammation and cancer are provided. The oligonucleotides are directed against nucleic acid sequences coding for a receptor selected from the group consisting of a CCR3 receptor and a common sub-unit of IL-3, IL-5 and GM-CSF receptors.
Abstract: The invention relates to therapeutic antisense oligonucleotides directed against genes encoding phosphodiesterases (PDE) and the use of these antisense oligonucleotides in combination. These antisense oligonucleotides may be used as analytical tools and/or as therapeutic agents in the treatment of disease associated with reduced cellular cAMP in a patient, such as inflammatory diseases of the respiratory tract including, for example, asthma, chronic obstructive pulmonary disease (COPD), acute respiratory distress syndrome, bronchitis, chronic bronchitis, silicosis, pulmonary fibrosis, lung allograft rejection, allergic rhinitis and chronic sinusitis as well as other conditions in which an increase in cyclic AMP or a decrease in PDE levels is beneficial.
Type:
Grant
Filed:
May 18, 2007
Date of Patent:
July 19, 2011
Assignee:
Topigen Pharmaceuticals, Inc.
Inventors:
Paolo Renzi, Luc Paquet, Helene D'Anjou
Abstract: The invention relates to therapeutic antisense oligonucleotides directed against genes encoding phosphodiesterases (PDE) and the use of these antisense oligonucleotides in combination. These antisense oligonucleotides may be used as analytical tools and/or as therapeutic agents in the treatment of disease associated with reduced cellular cAMP in a patient, such as inflammatory diseases of the respiratory tract including, for example, asthma, chronic obstructive pulmonary disease (COPD), acute respiratory distress syndrome, bronchitis, chronic bronchitis, silicosis, pulmonary fibrosis, lung allograft rejection, allergic rhinitis and chronic sinusitis as well as other conditions in which an increase in cyclic AMP or a decrease in PDE levels is beneficial.
Type:
Application
Filed:
May 18, 2007
Publication date:
April 14, 2011
Applicant:
TOPIGEN PHARMACEUTICALS INC.
Inventors:
Paolo Renzi, Luc Paquet, Helene D'Anjou
Abstract: The invention relates to therapeutic antisense oligonucleotides directed against genes encoding phosphodiesterases (PDE) and the use of these antisense oligonucleotides in combination. These antisense oligonucleotides may be used as analytical tools and/or as therapeutic agents in the treatment of disease associated with reduced cellular cAMP in a patient, such as inflammatory diseases of the respiratory tract including, for example, asthma, chronic obstructive pulmonary disease (COPD), acute respiratory distress syndrome, bronchitis, chronic bronchitis, silicosis, pulmonary fibrosis, lung allograft rejection, allergic rhinitis and chronic sinusitis as well as other conditions in which an increase in cyclic AMP or a decrease in PDE levels is beneficial.
Type:
Application
Filed:
May 18, 2007
Publication date:
February 25, 2010
Applicant:
TOPIGEN PHARMACEUTICALS INC.
Inventors:
Paolo Renzi, Luc Paquet, Helene D'Anjou
Abstract: Small interfering ribonucleic acid duplexes that inhibit gene expression containing at least one arabinose modified nucleotide are provided. Preferably, the duplexes contain ribonucleotides at least one arabinose modified nucleotide is 2?-deoxy-2?-fluoroarabinonucleotide (FANA) nucleotide.
Abstract: Antisense oligonucleotides for treating and/or preventing at least one of asthma, allergy, hypereosinophilia, general inflammation and cancer are provided. The oligonucleotides are directed against nucleic acid sequences coding for a receptor selected from the group consisting of a CCR3 receptor and a common sub-unit of IL-3, IL-5 and GM-CSF receptors.
Abstract: There is provided a pharmaceutical composition for treating respiratory disease comprising an NO-donating steroid and at least one bronchodilator. Also provided is a method for treating respiratory diseases associated with inflammation comprising administering an NO-donating steroid with at least one bronchodilator. Method of use of the combination of an NO-donating compound, and a steroid with at least one bronchodilator for treating respiratory disease is also provided.
Type:
Application
Filed:
August 8, 2008
Publication date:
April 2, 2009
Applicant:
Topigen Pharmaceuticals Inc.
Inventors:
Paolo Renzi, Luc Paquet, Nicolay Ferrari
Abstract: There are herein provided methods of treatment and nitric oxide donating compositions of matter for the treatment of respiratory diseases and associated conditions.
Type:
Application
Filed:
August 8, 2008
Publication date:
April 2, 2009
Applicant:
Topigen Pharmaceuticals Inc.
Inventors:
Paolo Renzi, Rene Pageau, Mark Parry-Billings
Abstract: A user system includes terminal equipment, a removable integrated circuit card and a removable memory card configured to cooperate with the terminal equipment, a card link application provided in the integrated circuit card to establish and manage a secure logical connection between the integrated circuit card and the memory card through the terminal equipment, and an application programming interface provided in the terminal equipment to receive and execute commands from the card link application and to cooperate with the card link application to establish the secure logical connection between the integrated circuit card and the memory card through the first terminal equipment.